𝔖 Bobbio Scriptorium
✦   LIBER   ✦

CXCR7 transcription in human non-small cell lung cancer and tumor-free lung tissues; possible regulation upon chemotherapy

✍ Scribed by Torsten Goldmann; Daniel Drömann; Janine Radtke; Sebastian Marwitz; Dagmar S. Lang; Holger Schultz; Ekkehard Vollmer

Publisher
Springer
Year
2008
Tongue
English
Weight
150 KB
Volume
452
Category
Article
ISSN
1432-2307

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CD80 expression in an HLA-A2-positive hu
CD80 expression in an HLA-A2-positive human non-small cell lung cancer cell line enhances tumor-specific cytotoxicity of HLA-A2-positive T cells derived from a normal donor and a patient with non-small cell lung cancer
✍ Dale L. Bixby; John R. Yannelli 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 185 KB 👁 2 views

To generate non-small cell lung cancer (NSCLC)-reactive lymphocytes, we transfected an HLA-A2-expressing human NSCLC line (1355) with the cDNA encoding the lymphocyte co-stimulatory molecule CD80. Following selection in G418, 1355.7 demonstrated stable cell-surface expression of CD80. Allogeneic mix

Gefitinib and chemotherapy combination s
Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response
✍ Jean-Gabriel Judde; Magali Rebucci; Nicolas Vogt; Patricia de Cremoux; Alain Liv 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 458 KB

## Abstract The epidermal growth factor receptor (EGFR) signaling pathway is often activated in NSCLC, and thus represents a promising therapeutic target. We studied the antitumor activity of gefitinib (Iressa™), an orally active EGFR‐tyrosine kinase inhibitor, alone and in combination with standar